Upper respiratory tract infection

Insights on the Cough Syrup Global Market to 2027 - Increasing Prevalence of Upper Respiratory Tract Infection and Other Respiratory Disorders Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Food, Beverage, Retail, URTI, Growth, Degenerative disease, COVID-19, Cough, Pharmacy, Honey, Upper respiratory tract infection, Prevalence, Tobacco, OTC, Air pollution, Agent handling, Mucus, Pharmaceutical industry

Cough syrup is a combination drug that is used to provide temporary relief from cough, common cold, hay fever and other respiratory allergies.

Key Points: 
  • Cough syrup is a combination drug that is used to provide temporary relief from cough, common cold, hay fever and other respiratory allergies.
  • The suppressants aid in alleviating the symptoms of dry cough by minimizing the activity of the cough reflex and reducing the urge to cough.
  • The increasing prevalence of upper respiratory tract infection (URTI) and other respiratory disorders across the globe is one of the key factors driving the growth of the market.
  • Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth.

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Retrieved on: 
Wednesday, December 7, 2022
Online, Bronchitis, Moyamoya disease, Atrial fibrillation, Simvastatin, Kidney, Cardiovascular disease, National Center for Health Research, Shoulder, Abdominal pain, Mortality, ANN, Pregnancy, Health, ATP, Security (finance), ESPR, Uric acid, Rotator cuff, Drug, Diet, National Center for Health Statistics, Back pain, Pravastatin, Centers for Disease Control and Prevention, Pain, CDC, World Heart Federation, Spasm, Gout, Cholesterol, Lactation, Fetus, Disease, Upper respiratory tract infection, Achilles tendon, Concentration ratio, GA, Growth, CLEAR, Risk, Medical statistics, COVID-19, Patient, Anemia, Tendon rupture, Pharmaceutical industry, Dietary supplement, Hyperuricemia, Bempedoic acid, Death, Esperies

ANN ARBOR, Mich., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL compared to placebo.

Key Points: 
  • CLEAR Outcomes further strengthens the clinical evidence supporting the role of bempedoic acid for patients.”
    Cardiovascular disease remains the number one killer globallyi.
  • A large proportion of patients at risk for cardiovascular events based on elevated LDL-cholesterol and apolipoprotein b are not adequately treated with existing therapies.
  • Despite recent therapeutic advances, there remains a significant need for new treatment options to help improve long-term cardiovascular outcomesii.
  • Limitations of Use: The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Monday, November 21, 2022
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Marketing, Cytokine, Patent, International, Hepatitis B virus, Human, Severe acute respiratory syndrome coronavirus 2, Safety, Security (finance), Upper respiratory tract infection, Immunodeficiency, Risk, Plasma, Vaccine, PK, Respiratory tract infection, Conference, COVID, Research, SPRINT, Asthma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Alpha, COVID-19, Degenerative disease, FDA, Fast Track, Omicron, Heart, Medication, Glecaprevir/pibrentasvir, Food, CARES Act, Pharmacokinetics, HCV, COPD, Urinary tract infection, RNA, Drug discovery, Chronic obstructive pulmonary disease, Respiratory syncytial virus, HBV, AbbVie, RSV, Immunity, Vaccination, Virology, Infection, Patient, Pharmaceutical industry, Video game, Perfume, Dietary supplement

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2022.

Key Points: 
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2022.
  • For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021.
  • For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021.
  • For the twelve months ended September 30, 2022, general and administrative expenses were $45.5 million compared to $32.5 million in 2021.

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

Retrieved on: 
Monday, November 14, 2022
Biotechnology, General Health, Pharmaceutical, Health, Puberty, Multimedia, Headache, Urinary incontinence, Overactive bladder, Incontinence, Nasal congestion, Mayo Clinic, Upper respiratory tract infection, Vitamin, Digoxin, PureWow, Lisa Filipetto, Urinary urgency, InStyle, Partnership, Liver, Family medicine, Vibegron, Good Housekeeping, THINX, Travel, Diarrhea, Publication, FDA, Sore throat, Kidney, OAB, Commercial, Orange County Business Journal, WWD, Menstruation, Urine, PLOS One, Urination, Breast milk, NYSE, Medicine, Thinx, Science, Urinary retention, BioMed Central, Nausea, The Journal of Urology, Allergy, Research, 100 Best Workplaces in Europe, Urinary tract infection, Gesellschaft mit beschränkter Haftung, Leakage, Patient, Pharmaceutical industry, Phosphorus, Management, Dietary supplement, Medical device, VideoRay UROVs, Urology

View the full release here: https://www.businesswire.com/news/home/20221114005347/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221114005347/en/
    Urovant Sciences Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season (Graphic: Business Wire)
    November is Bladder Health Awareness Month and its also the start of holiday and winter travel.
  • To help people learn more about OAB and ways to manage symptoms, a free travel kit is available on TimeToGo.com.
  • Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

New study reveals the extent of antibiotic misuse for a common sore throat, fuelling the 3rd leading cause of death worldwide

Retrieved on: 
Friday, November 18, 2022
Suffering, Sore throat, Anxiety, Common, Infection, GRIP, WAAW, Death, Workforce, STAR, Confusion, Education, Multimedia, Antimicrobial resistance, Sore, Upper respiratory tract infection, Virus, Pharmaceutical industry, Dietary supplement, Poultry, Trapping

Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.

Key Points: 
  • Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.
  • The STAR study findings suggest that a misunderstanding of how to treat sore throats is contributing to antibiotic overuse.
  • GRIP is calling for awareness and education on appropriate antibiotic use and urging young people to ask questions to help fight antibiotic resistance."
  • For more information or interviews with GRIP experts Sabiha Essack & Martin Duerden: [email protected] , +44 20 8154 6389
    View original content to download multimedia: https://www.prnewswire.com/news-releases/new-study-reveals-the-extent-of...

New study reveals the extent of antibiotic misuse for a common sore throat, fuelling the 3rd leading cause of death worldwide

Retrieved on: 
Friday, November 18, 2022
Suffering, Sore throat, Anxiety, Common, Infection, GRIP, WAAW, Death, Workforce, STAR, Confusion, Education, Antimicrobial resistance, Sore, Upper respiratory tract infection, Virus, Pharmaceutical industry, Dietary supplement, Poultry, Trapping

Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.

Key Points: 
  • Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.
  • The STAR study findings suggest that a misunderstanding of how to treat sore throats is contributing to antibiotic overuse.
  • GRIP is calling for awareness and education on appropriate antibiotic use and urging young people to ask questions to help fight antibiotic resistance."
  • For more information or interviews with GRIP experts Sabiha Essack & Martin Duerden: [email protected] , +44 20 8154 6389

RemeGen Biosciences to Present New Data Updates in ACR 2022

Retrieved on: 
Friday, November 11, 2022
ACR, Immunoglobulin G, Multimedia, Control, Ageing, Systematic, BAFF-R, Rheumatoid arthritis, B cell, Survival, Fast track (FDA), BCMA, IgA nephropathy, PPS, National Medical Products Administration, Șaeș, III, Urinary tract infection, Immunoglobulin M, Adult, Research, Autoimmunity, American College of Rheumatology, Patient, SAN, NRDL, Lymphocyte, B-cell activating factor, CAML, ANA, Safety, SLE, American College, NMPA, Mab, Antibody, TACI, Sjögren syndrome, Population, AES, PSS, APRIL, Upper respiratory tract infection, Immunoglobulin A, Week, Pharmaceutical industry, Online shopping

This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.

Key Points: 
  • This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.
  • Telitacicept for Systematic Lupus Erythematosus, data from phase III trial
    This is a 52-week, randomized, double-blind, placebo-controlled, phase III clinical trial (NCT04082416).
  • RemeGen, Ltd. ("RemeGen") is a leading biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions.
  • Since its inception in 2008, RemeGen has created more than 10 novel drug molecules in various clinical development stages.

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Perception, Gesellschaft mit beschränkter Haftung, Medicine, Overactive bladder, Plasma, Liver, Breast milk, Instagram, Safety, 100 Best Workplaces in Europe, Vitamin, Taste, AES, Headache, AUC, Kopp, Adult, Orange County Business Journal, Drug development, I, Sex, Diarrhea, Digoxin, Neurogenic bladder dysfunction, FDA, Burden, Patient, Food additive, Urination, Food, Kidney, Urinary incontinence, Man, Science, Twitter, OAB, Urinary urgency, Vibegron, Nausea, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sore throat, Urine, Urinary retention, Prevalence, NYSE, Upper respiratory tract infection, Nasal congestion, Urinary tract infection, Vats, Allergy, Dysphagia, Nocturia, Constipation, Public health, Pharmaceutical industry, Medical imaging, Perfume, Dietary supplement, Sexton, Cmax

In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

Key Points: 
  • In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.
  • All patients received one treatment with intact tablet and one with crushed tablet, mixed with applesauce.
  • Additional reported TEAEs experienced by 2 participants were constipation (crushed, 13.3%; intact 6.7%) and nausea (crushed 6.7%, intact 0%) .
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

BeniCaros Accelerates Protective Immune Responses and Helps Healthy Individuals Maintain Quality of Life, New Clinical Data Finds

Retrieved on: 
Monday, October 17, 2022
Quality of life, Gene expression, Quality, Randomness, Infection, Common, Research, Nose, Rhinovirus, Immune system, Exercise, Health, Upper respiratory tract infection, GLOBE, Nutrient, Degenerative disease, Biomarker, Functional food, Cough, Dietary supplement, Vaccine

The paper is titled, Effects of Dietary Supplementation with Carrot-Derived Rhamnogalacturonan-I (cRG-I) on Accelerated Protective Immune Responses and Quality of Life in Healthy Volunteers Challenged with Rhinovirus in a Randomized Trial.

Key Points: 
  • The paper is titled, Effects of Dietary Supplementation with Carrot-Derived Rhamnogalacturonan-I (cRG-I) on Accelerated Protective Immune Responses and Quality of Life in Healthy Volunteers Challenged with Rhinovirus in a Randomized Trial.
  • Our research shows that BeniCaros supports and accelerates healthy immune responses when they are needed most, said Joana Carneiro, NutriLeads Chief Executive Officer.
  • These latest data illustrate the ways in which BeniCaros helps individuals live their lives so nothing slows them down.
  • Biological study data show BeniCaros supports a cascade of protective immune responses in the presence of a health challenge.

Outlook on the Cystic Fibrosis Global Market to 2030 - Featuring Roche, Nestle Health Science, AbbVie and Viatris Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Adoption, Quality of life, Revenue, AstraZeneca, Disease, Growth, Hospital, Diagnosis, AbbVie, Cystic fibrosis, Novartis, CFTR, CAGR, Roche, Patient, Pfizer, COVID-19, Blood pressure, Mortality, Chest pain, Gilead Sciences, Genetic disorder, Liver, Horizon Therapeutics, Industry, Teva Pharmaceuticals, Upper respiratory tract infection, Awareness, Incidence, MedImmune, Inc. v. Genentech, Inc., Degenerative disease, Compliance, Vertex Pharmaceuticals, Pharmaceutical industry, Dietary supplement, Bayer

Rising awareness about cystic fibrosis and growing adoption of drug therapies are the prominent factors driving the cystic fibrosis market growth.

Key Points: 
  • Rising awareness about cystic fibrosis and growing adoption of drug therapies are the prominent factors driving the cystic fibrosis market growth.
  • The widespread availability of different cystic fibrosis treatment options will expand the market size over the coming years.
  • Rising innovation in the development of new therapies and drug products to cure cystic fibrosis is anticipated to foster growth in the cystic fibrosis market over the analysis period.
  • The publisher has segmented the cystic fibrosis market report based on drug class, route of administration, distribution channel, and region:
    Cystic Fibrosis Market, By Drug Class (Revenue - USD Billion, 2018 - 2030)